Randomized Study to Characterize Glycemic Control and Short-Term Pulmonary Function in Patients with Type 1 Diabetes Receiving Inhaled Human Insulin (Exubera) | Zendy

Paul Norwood | Zendy; R Dumas | Zendy; William T. Cefalu | Zendy; JeanFrançois Yale | Zendy; Richard D. England | Zendy; Richard J. Riese | Zendy; John G. Teeter | Zendy

Open Access

Randomized Study to Characterize Glycemic Control and Short-Term Pulmonary Function in Patients with Type 1 Diabetes Receiving Inhaled Human Insulin (Exubera)

Author(s) -

Paul Norwood,

R Dumas,

William T. Cefalu,

JeanFrançois Yale,

Richard D. England,

Richard J. Riese,

John G. Teeter

Publication year - 2006

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2006-0631

Subject(s) - type 2 diabetes , medicine , hypoglycemia , insulin , glycemic , diabetes mellitus , gastroenterology , endocrinology , pharmacology

Previous studies with inhaled human insulin [Exubera (EXU); insulin human (recombinant DNA origin) Inhalation Powder, Pfizer Inc., New York, NY; Nektar Therapeutics, San Carlos, CA) show comparable efficacy to sc insulin and small declines in pulmonary function in type 1 and 2 diabetes. This is a detailed characterization of short-term efficacy and pulmonary safety profile of EXU.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research